{
    "2018-07-06": [
        [
            {
                "time": "",
                "original_text": "[强于大市评级]一名普通医药分析师《药神》观影启示录(医药生物行业)：格列卫引发的对立与救赎",
                "features": {
                    "keywords": [
                        "医药",
                        "生物行业",
                        "格列卫",
                        "对立",
                        "救赎"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业跌2.53%，创近4个月新低，报52.00元",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "下跌",
                        "新低"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}